|
11 Sep 2025 |
SRF
|
Consensus Share Price Target
|
2985.50 |
3104.79 |
- |
4.00 |
hold
|
|
|
|
|
25 Jul 2023
|
SRF
|
ICICI Securities Limited
|
2985.50
|
2135.00
|
2164.10
(37.96%)
|
Target met |
Hold
|
|
|
SRF’s Q1FY24 print for its chemical business (EBIT down 11.6% YoY) was below our expectations and was hurt from lower sales in ref-gas (both volume and price declined) while specialty sales were hurt from destocking. Company anticipates specialty chemicals sales to be impacted over the next few quarters though it has not seen any order cancellation, which implies steady underlying demand.
|
|
27 Jun 2023
|
SRF
|
Motilal Oswal
|
2985.50
|
2580.00
|
2308.35
(29.33%)
|
Target met |
Neutral
|
|
|
|
|
23 May 2023
|
SRF
|
Chola Wealth Direct
|
2985.50
|
3300.00
|
2470.80
(20.83%)
|
|
Buy
|
|
|
|
|
11 May 2023
|
SRF
|
Edelweiss
|
2985.50
|
2856.00
|
2560.95
(16.58%)
|
|
Buy
|
|
|
Specialty Chemicals Business continues to outperform
|
|
11 May 2023
|
SRF
|
ICICI Direct
|
2985.50
|
3000.00
|
2560.95
(16.58%)
|
|
Buy
|
|
|
|
|
10 May 2023
|
SRF
|
ICICI Securities Limited
|
2985.50
|
2520.00
|
2571.25
(16.11%)
|
Target met |
Hold
|
|
|
SRF’s Q4FY23 print for chemical business (EBIT up 47% YoY) benefited from strong ref gas and fluorospecialty business. Despite the risk of pricing in ref-gas and down- cycle in agro-chemicals, company has guided for chemical segment revenue growth of 20%+, and EBIT margin improvement in FY24 (vs FY23).
|
|
10 May 2023
|
SRF
|
Motilal Oswal
|
2985.50
|
2680.00
|
2571.25
(16.11%)
|
Target met |
Neutral
|
|
|
|
|
14 Mar 2023
|
SRF
|
BP Wealth
|
2985.50
|
2803.00
|
2305.40
(29.50%)
|
|
Buy
|
|
|
|
|
01 Feb 2023
|
SRF
|
ICICI Direct
|
2985.50
|
2550.00
|
2224.65
(34.20%)
|
Target met |
Buy
|
|
|
|
|
31 Jan 2023
|
SRF
|
Motilal Oswal
|
2985.50
|
2450.00
|
2182.45
(36.80%)
|
Target met |
Neutral
|
|
|
|